This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HyperAcute Pancreas

NewLink Genetics Corporation

Drug Names(s): algenpantucel-L, HyperAcute-Pancreatic Cancer Vaccine

Description: HyperAcute cancer immunotherapies are off-the-shelf products composed of a mixture of irradiated, allogeneic, whole cancer cells that have been genetically modified to add a(1,3)-Galactosyl (aGal) residues to cell-surface lipids and proteins. The aGal epitopes function as a molecular adjuvant, effectively harnessing the mechanism responsible for hyperacute rejection of xenotransplants.

NewLink's HyperAcute technology yields a unique combination of advantages, including: